Researchers develop molecule for potential drug in India

Researchers develop molecule for potential drug in India
x
Highlights

Shiv Nadar University in Greater Noida on Monday announced that its researchers have created a molecule that has the potential to be developed into a drug that can cure Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients

Greater Noida : Shiv Nadar University in Greater Noida on Monday announced that its researchers have created a molecule that has the potential to be developed into a drug that can cure Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients.

The team found a set of New Chemical Entities (NCEs) with the ability to cure Acute Respiratory Distress Syndrome (ARDS) or Acute Lung Injury (ALI) induced by COVID-19 (SARS-CoV-2) or other Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), which are also caused by coronaviruses.

The two-fold strategy devised by the research team involved the application of the NCEs to inhibit attachment, entry and infection of the new SARS-CoV-2 through a known target on the virus and co-administration of a known drug (that modulates a set of hormonal receptors in human) and these NCEs to attenuate ARDS caused by novel coronavirus.

"We hope our therapeutic approach will unravel solutions against maladies associated with acute respiratory distress syndrome. Our aim is to conclude the preclinical studies by the end of this year, post which the new compound will potentially be ready for the next stage of development along with human trials," study researcher Dr Subhabrata Sen, Professor, Department of Chemistry at Shiv Nadar University said in a statement.

According to the University, the discovery has come out of months of research, conceptualising small molecule modulators of a set of hormonal receptors in humans and how they are connected with potential receptors in the lungs that act as the entry of SARS-CoV-2, SARS and MERS in the human host.

Additionally, the researchers looked into the pathophysiological condition of lungs during respiratory failure. This included extensive investigations of lung specimens from patients who were retrospectively found to have COVID-19.

Show Full Article
Print Article
Next Story
More Stories
ADVERTISEMENT
ADVERTISEMENTS